90.50
+5.735(+6.77%)
Currency In USD
| Previous Close | 84.76 |
| Open | 84.12 |
| Day High | 90.85 |
| Day Low | 83.09 |
| 52-Week High | 90.85 |
| 52-Week Low | 10.14 |
| Volume | 2.13M |
| Average Volume | 695,512 |
| Market Cap | 2.29B |
| PE | -11.86 |
| EPS | -7.63 |
| Moving Average 50 Days | 65.62 |
| Moving Average 200 Days | 35.42 |
| Change | 5.74 |
If you invested $1000 in Cidara Therapeutics, Inc. (CDTX) 10 years ago, it would be worth $364.02 as of September 29, 2025 at a share price of $90.495. Whereas If you bought $1000 worth of Cidara Therapeutics, Inc. (CDTX) shares 5 years ago, it would be worth $1,544.28 as of September 29, 2025 at a share price of $90.495.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations
GlobeNewswire Inc.
Sep 25, 2025 8:01 PM GMT
- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept.
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
GlobeNewswire Inc.
Sep 24, 2025 11:00 AM GMT
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval - Pha
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
GlobeNewswire Inc.
Sep 17, 2025 12:00 PM GMT
- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation - Preclinical data demonstrating potential efficacy of CD388 to prevent H5N1 infection featured